Financial StabilityOPK has a substantial cash reserve following the sale of certain diagnostic businesses, which strengthens its financial position.
PartnershipsThe collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies could potentially exceed $1B in value.
ProfitabilityReaching profitability will not only provide a self-sustainable path for an important value driver at OPK, it will also offset the development costs needed to pursue its therapeutic goals.